Navigation Links
For Prevention of Stroke, Surveyed Cardiologists and PCPs Expect to Prescribe Xarelto to Approximately One-Third of Newly-Diagnosed Atrial Fibrillation Patients
Date:4/2/2009

However, Most Surveyed MCOs Say They Will Not Provide Reimbursement for Xarelto if its Only Advantage in Stroke Prevention is Greater Convenience, According to a New Report from Decision Resources

WALTHAM, Mass., April 2 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for prevention of stroke, surveyed cardiologists estimate they will prescribe Bayer/Johnson & Johnson's Xarelto to 36 percent of newly-diagnosed atrial fibrillation patients, while primary care physicians (PCPs) estimate they will prescribe Xarelto to 29 percent of newly-diagnosed atrial fibrillation patients. Additionally, surveyed PCPs indicate they will prescribe Boehringer Ingelheim's Pradaxa to 28 percent of newly-diagnosed atrial fibrillation patients.

The new Physician & Payer Forum report entitled Novel Anticoagulants for Venous Thromboembolism and Stroke Prevention in Atrial Fibrillation: Will Prescribers' and Payers' Attitudes Promote or Prevent a Shift Away From Warfarin and Heparins? finds that Xarelto is the most popular emerging antithrombotic therapy among surveyed clinicians. Despite the proven effectiveness and widespread use of vitamin K antagonists such as warfarin (Bristol-Myers Squibb's Coumadin) for stroke prevention and heparins for venous thromboembolism prevention (VTE), both drug classes have drawbacks in safety and/or drug delivery that compromise optimal anticoagulation.

"A multitude of new anticoagulants currently in late-stage development are seeking to overcome these problems and developers of these agents could capitalize on the commercial potential offered by the large patient populations with atrial fibrillation or nonsurgical inpatients at risk of VTE," said Decision Resources Director Nikhil Mehta, M.Eng. "However, existing anticoagulants are well established, and older versions of these drugs are inexpensive--these factors beg the question as to whether or not prescribers and payers will support the uptake of new, more-expensive agents in this market."

The report finds that a third or fewer of surveyed managed care organizations' (MCO) pharmacy directors would place Xarelto, Pradaxa, or Bristol-Myers Squibb/Pfizer's apixaban on Tier 2 of their formularies if these agents are proven only to be equal to warfarin for both stroke prevention efficacy and bleeding. If the only clear advantage of these novel oral anticoagulants over warfarin in stroke prevention is greater convenience (e.g. no routine monitoring or dose adjustment), most surveyed pharmacy directors say they would be unwilling to pay for greater convenience alone.

Novel Anticoagulants for Venous Thromboembolism and Stroke Prevention in Atrial Fibrillation: Will Prescribers' and Payers' Attitudes Promote or Prevent a Shift Away From Warfarin and Heparins is based on a U.S. survey of 50 cardiologists, 31 hospital internists who sit on their hospital pharmacy and therapeutics committees, 72 primary care physicians and 20 managed care organization (MCO) pharmacy directors. Their responses were compared to assess similarities and differences of opinion regarding clinical, economic and scientific factors.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                             Decision Resources, Inc.
    Christopher Comfort                            Elizabeth Marshall
    781-296-2597                                   781-296-2563
    ccomfort@dresources.com                        emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Trust for Americas Health Testifies before Congress on Building Prevention into Health Reform
2. Wyeth Submits Marketing Application to FDA for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Toddlers
3. Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
4. Siemens Highlights Cardiology Excellence from Prevention to Follow-up at ACC 2009
5. Especially Among Children, Prevention is Key to Halting Obesity Epidemic, President of American Dietetic Association Tells Congressional Subcommittee
6. Recondo Technology Announces Authorization and Denial Prevention Software Service
7. Licorice compound offers new cancer prevention strategy
8. Poison Prevention Requires Diligence
9. Salt in Processed Foods Focus of the 7th National Forum on Heart Disease and Stroke Prevention
10. Preventium is where the prevention of breast and prostate cancer begins
11. NSC Hosts National Poison Prevention Week News Conference, Tuesday, March 17
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... 2016 , ... Diagnotes, a leader in digital healthcare communications, ... system in South Carolina, to provide its secure mobile communication platform. , “Healthcare ... drives workflow efficiencies and improves provider and patient satisfaction,” said Dr. Todd Rowland, ...
(Date:5/3/2016)... ... May 03, 2016 , ... Each year, about 800,000 people suffer from cerebral ... United States and account for one death every four minutes. Many people who ... HCR ManorCare is launching a video series called “Your Brain,” in conjunction with its ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... industry, announced today that Legacy Health is expanding its use of Intrigma’s cloud-based ... a highly successful initial proof of concept. The Portland, Oregon based health system ...
(Date:5/3/2016)... ... 03, 2016 , ... Huntington Beach orthopedic doctor , Dr. Rick Pospisil, ... be used to diagnose and treat joint problems. During this procedure, Dr. Pospisil makes ... special lighting system and lens that illuminate and magnify the various structures in the ...
(Date:5/3/2016)... ... May 03, 2016 , ... Finding the right way to address a patient’s condition before it ... now getting on board. , “You do the right thing, at the right time, at ... down, not up,” said Leonard M. Fromer, MD, FAAFP, from Group Practice Forum. “Even if ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
(Date:4/28/2016)... 2016  Marking its one year anniversary since ... cancer risk test, Color Genomics announced ... highly impact the most common hereditary cancers affecting ... Test analyzes hereditary cancer risks for breast, colorectal, ... The Color Test is physician ordered and includes ...
(Date:4/28/2016)... , April 28, 2016  The blood testing ... million dollars, according to Kalorama Information and The Freedonia ... immunoassays and nucleic acid testing.  The healthcare research firm ... progress in developing blood collection stations and in improving ... in Kalorama Information,s report, Blood Testing Market ...
Breaking Medicine Technology: